Myriad Genetics' Strategic Growth Fuels Bullish Outlook
Myriad(MYGN) Seeking Alpha·2024-02-01 03:23
Yozayo In the field of genetic testing and precision medicine, Myriad Genetics (NASDAQ: NASDAQ:MYGN) is a progressive company, which can be observed in its steady double-digit revenue growth and the upward revision of revenue guidance for the next year. The financial results of the third quarter of 2023 of the company demonstrate a strong year-over-year growth in testing volumes in various segments, such as hereditary cancer, pharmacogenomics, and prenatal testing. This upward trend is not a temporary incre ...